Peptide LibraryProstamax
Also known as: Prostate bioregulator, Lys-Glu-Asp-Pro
Prostamax (also called Prostate bioregulator or Lys-Glu-Asp-Pro) is a khavinson prostate bioregulator. Prostamax is Lys-Glu-Asp-Pro, a synthetic tetrapeptide in the Khavinson series associated with prostate tissue. The proposed mechanism for the series is that short peptides enter the nucleus and act on chromatin and gene expression; for Prostamax the indexed work reports decondensation of heterochromatin in lymphocytes from people aged 75–88 in culture.
For research use only.
Key Facts
- CAS
- 473578-47-1
- Molecular Weight (MW)
- 487.5 g/mol
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Prostate epithelium (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 9
- Listed offers
- 9
- Median price per mg (peptide vials)
- $3.48/mg
- Typical $2.86–$3.96/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials7 vendors · median $3.48/mg
- Capsules1 vendor
Research summary
Prostamax is Lys-Glu-Asp-Pro (KEDP), a synthetic tetrapeptide sold as a prostate bioregulator in the Khavinson tradition. Its literature is cell-culture work, mostly on chromatin in lymphocytes from older people. It is not a treatment for benign prostatic hyperplasia or any other prostate condition, has no controlled trial evidence, and is not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies2 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Prostamax profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Prostamax dosage: no established human dose
Prostamax has no established human dosage. The indexed papers describe it as the synthetic tetrapeptide Lys-Glu-Asp-Pro from the Khavinson bioregulator series. No trial of it is registered on ClinicalTrials.gov and no study has given it to people. Its evidence is lab work on blood cells taken from older people, which tested the peptide in culture.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Prostamax is a short peptide from the Russian bioregulator research school. Its indexed literature is a few chromatin and calorimetry studies on human blood cells in the lab, mostly from that school and its collaborators. No study has given it to people or reported an animal dose. Nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| In vitro — chromosomes in cells from people aged 75–86 (2012)Preclinical · Preclinical cell-culture study | Cells from older people (75–86 years) treated in culture | Concentration not stated in the indexed abstract; added to cells, not given to a person | In vitro, added to culture medium | — | — | More sister chromatid exchanges and active nucleolar organiser regions, and less condensed pericentromeric heterochromatin | [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]. Georgian Med News. 2012. |
| In vitro — five short peptides on leukocyte chromatin from people aged 75–88 (2004)Preclinical · Preclinical cell-culture study | Leukocytes from people aged 75–88, treated in culture | Concentration not stated in the indexed abstract; added to cells, not given to a person | In vitro, added to culture medium | — | — | Activation of ribosomal genes and decondensation of chromatin, including chromosome 1 pericentromeric chromatin with prostamax | Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004. |
Where sources disagree
- Prostamax is sold with protocols, but no registered trial or indexed study reports a human dose.
- Descriptions of prostamax differ. The indexed papers name it as the synthetic tetrapeptide Lys-Glu-Asp-Pro, while some product descriptions call it a prostate tissue extract. Prostamax is also different from Prostatilen and Libidon.
- The prostate claims come from the series convention of linking each peptide to a tissue, not from a study of prostate outcomes.
Reconstitution
Common research vial sizes: 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 20 mg | 4 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Amino acid sequence | Lys-Glu-Asp-Pro (KEDP) |
|---|---|
| Molecular formula | C20H33N5O9 |
| Molecular weight | 487.5 g/mol |
| CAS number | 473578-47-1 |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 9848296 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Prostamax is Lys-Glu-Asp-Pro, a synthetic tetrapeptide in the Khavinson series associated with prostate tissue. The proposed mechanism for the series is that short peptides enter the nucleus and act on chromatin and gene expression; for Prostamax the indexed work reports decondensation of heterochromatin in lymphocytes from people aged 75–88 in culture. No receptor or signalling pathway has been identified, and none of this has been tested in a clinical study.
Origin
Synthetic short peptide.
Targets
Studies
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]
- Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax
- [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ]
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]
- Effects of short peptides on lymphocyte chromatin in senile subjects
Research statistics
6 PubMed publications · 0.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Prostamax is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Prostamax side effects
Prostamax has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Prostamax: frequently asked questions
What is Prostamax?
Peptide preparation derived from prostate tissue and sold as a prostate bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, so no specific mechanism can be attributed to it. It is not a treatment for benign prostatic hyperplasia or any other prostate condition, has no controlled trial evidence, and is not FDA-approved.
How does Prostamax work?
Prostamax is a peptide preparation derived from prostate tissue and marketed in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single characterised compound, so no receptor, sequence or signalling mechanism can be specified for it.
Is Prostamax FDA approved?
No. Prostamax is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Prostamax?
Compounds most often compared with Prostamax include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)] — Georgian Med News, 2012External reference
- Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax — Georgian Med News, 2009External reference
- [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ] — Biofizika, 2004External reference
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats] — Adv Gerontol, 2006External reference
- Effects of short peptides on lymphocyte chromatin in senile subjects — Bull Exp Biol Med, 2004External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Prostamax profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Prostamax research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →